MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Novel RAB39B stop mutation in patient with typical Early-Onset Parkinson’s disease

J. Jacobson, C. Piat, O. Ross, R. Savica (Rochester, USA)

Meeting: 2023 International Congress

Abstract Number: 1124

Keywords: Parkinson’s

Category: Parkinson's Disease: Genetics

Objective: N/A

Background: RAB proteins are small guanosine triphosphatases (GTPases) that are ubiquitous and expressed in all cell types regulating vesicular transport and intracellular membrane trafficking. When expressed in the brain, they exert more specific functions such as neuronal growth and development. Mutations in the RAB39B gene were initially identified in X-linked mental retardation. More recently, two separate families from Australia and Wisconsin were observed to have RAB39B mutations causing early-onset parkinsonism with varying level of intellectual disability in two males. Neuropathologic evaluation found widespread a-synuclein. There is increasing evidence that RAB39B mutations may play a role in archetypal presentation Parkinson’s disease (PD), and herein we report a novel loss-of-function mutation in RAB39B in a female patient with typical early-onset Parkinson’s disease.

Method: N/A

Results: A 41-year-old otherwise healthy female from the Dakotas presented with reduced dexterity in the right upper limb and mixed tremor that worsened over 8 months. She is of British heritage with no family history of PD. Her son has mild intellectual disability and ADHD. On exam, patient exhibited hypomimia, hypokinetic dysarthria with right greater than left bradykinesia and mixed tremor. Her initial MDS-UPDRS score was 40. DaTscan showed reduced radiotracer uptake in the left greater than right putamen; treatment with carbidopa/levodopa conferred excellent response. Genetic testing revealed pathogenic heterozygous mutation Exon 1 c. 188G>A (p.Trp63) in the RAB39B gene.

Conclusion: Mutation of RAB39B may be a very rare cause of typical PD with pathogenesis thought to be due to disruption of a-synuclein homeostasis. Our case reports a novel mutation in the RAB39B gene. Screening of RAB39B mutation should be considered a possibility, although rare, in cases of typical early-onset PD.

To cite this abstract in AMA style:

J. Jacobson, C. Piat, O. Ross, R. Savica. Novel RAB39B stop mutation in patient with typical Early-Onset Parkinson’s disease [abstract]. Mov Disord. 2023; 38 (suppl 1). https://www.mdsabstracts.org/abstract/novel-rab39b-stop-mutation-in-patient-with-typical-early-onset-parkinsons-disease/. Accessed May 17, 2025.
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2023 International Congress

MDS Abstracts - https://www.mdsabstracts.org/abstract/novel-rab39b-stop-mutation-in-patient-with-typical-early-onset-parkinsons-disease/

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Survey-Based study of marijuana used in Parkinson’s Disease patients
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Life expectancy with and without Parkinson’s disease in the general population
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley